Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab and Lazertinib + Chemotherapy in EGFR-Mutated NSCLC After Osimertinib Failure
NCT04988295Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Bispecific Antibodies, Orthosteric Ligands
- Countries
- 29
01
Overview
Phase 3, randomised, open-label trial of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free Survival and Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events. Started Nov 2021; status: active, not recruiting.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04988295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988295.